Compare ACAD & DAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACAD | DAN |
|---|---|---|
| Founded | 1993 | 1904 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | 2000 | 1998 |
| Metric | ACAD | DAN |
|---|---|---|
| Price | $20.66 | $32.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 5 |
| Target Price | $30.45 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.49% |
| EPS Growth | 69.12 | ★ 264.10 |
| EPS | ★ 2.30 | 0.64 |
| Revenue | $726,437,000.00 | ★ $7,500,000,000.00 |
| Revenue This Year | $18.52 | $1.92 |
| Revenue Next Year | $11.34 | $3.60 |
| P/E Ratio | ★ $8.82 | $50.41 |
| Revenue Growth | ★ 40.45 | N/A |
| 52 Week Low | $14.08 | $10.11 |
| 52 Week High | $28.35 | $36.28 |
| Indicator | ACAD | DAN |
|---|---|---|
| Relative Strength Index (RSI) | 36.97 | 46.76 |
| Support Level | $20.45 | $28.30 |
| Resistance Level | $22.75 | $36.28 |
| Average True Range (ATR) | 0.90 | 1.26 |
| MACD | -0.15 | -0.35 |
| Stochastic Oscillator | 18.76 | 26.62 |
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.